Scholar Rock Holding (SRRK) Other Non-Current Assets (2017 - 2026)
Scholar Rock Holding's quarterly Other Non-Current Assets came in at $3.8 million in Q1 2026, up 58.16% year-on-year from $2.4 million in Q1 2025, and up 530.3% quarter-over-quarter from $604000.0 in Q4 2025.
Scholar Rock Holding has reported Other Non-Current Assets for 10 years, with the latest figure at $3.8 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 58.16% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.8 million (up 58.16% YoY), and the FY2025 full-year result was $604000.0, down 74.91% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $3.8 million, up from $604000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $3.8 million in Q3 2025, with the low at $604000.0 in Q4 2025.
- Average Other Non-Current Assets over 5 years is $2.5 million, with a median of $2.5 million recorded in 2022.
- Year-over-year, Other Non-Current Assets surged 150.8% in 2022 and slumped 74.91% in 2025.
- Tracing SRRK's Other Non-Current Assets over 5 years: stood at $2.5 million in 2022, then slipped by 3.64% to $2.4 million in 2023, then changed by 0.0% to $2.4 million in 2024, then tumbled by 74.91% to $604000.0 in 2025, then soared by 530.3% to $3.8 million in 2026.
- The last three Other Non-Current Assets figures came in at $3.8 million (Q1 2026), $604000.0 (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | 3.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.81 Mn |
| Dec 31, 2025 | 604,000.00 |
| Sep 30, 2025 | 3.81 Mn |
| Jun 30, 2025 | 2.96 Mn |
| Mar 31, 2025 | 2.41 Mn |
| Dec 31, 2024 | 2.41 Mn |
| Sep 30, 2024 | 2.41 Mn |
| Jun 30, 2024 | 2.41 Mn |
| Mar 31, 2024 | 2.41 Mn |
| Dec 31, 2023 | 2.41 Mn |
| Sep 30, 2023 | 2.61 Mn |
| Jun 30, 2023 | 2.61 Mn |
| Mar 31, 2023 | 2.50 Mn |
| Dec 31, 2022 | 2.50 Mn |
| Sep 30, 2022 | 2.50 Mn |
| Jun 30, 2022 | 2.50 Mn |
| Mar 31, 2022 | 2.50 Mn |
| Dec 31, 2021 | 2.50 Mn |
| Sep 30, 2021 | 2.50 Mn |
| Jun 30, 2021 | 2.50 Mn |
| Mar 31, 2021 | 996,000.00 |
| Dec 31, 2020 | 1.02 Mn |
| Sep 30, 2020 | 1.05 Mn |
| Jun 30, 2020 | 1.06 Mn |
| Mar 31, 2020 | 2.50 Mn |
| Dec 31, 2019 | 98,000.00 |
| Sep 30, 2019 | 85,000.00 |
| Jun 30, 2019 | 205,000.00 |
| Mar 31, 2019 | 205,000.00 |
| Dec 31, 2018 | 205,000.00 |
| Sep 30, 2018 | 205,000.00 |
| Jun 30, 2018 | 205,000.00 |
| Dec 31, 2017 | 50,000.00 |